Lv1
20 积分 2024-04-22 加入
Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases
1个月前
已完结
Pathophysiological advances in membranous nephropathy: time for a shift in patient's care
1个月前
已完结
POS0230 DISAGREEMENT BETWEEN PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OVER TIME IN PSORIATIC ARTHRITIS: INSIGHT INTO TREATMENT PRIORITIES
2个月前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
2个月前
已完结
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
2个月前
已完结
The Role of TNF Superfamily Member 13 in the Progression of IgA Nephropathy
2个月前
已完结
Targeting B Cells and Plasma Cells in Glomerular Disease
2个月前
已完结
Tegoprazan-based versus esomeprazole-based triple therapy plus bismuth for first-line Helicobacter pylori eradication: A nationwide, multicenter, double-blind, double-dummy, randomized controlled trial
4个月前
已完结
Randomized, Double-Blind, Active-Controlled Phase 3 Study to Evaluate Efficacy and Safety of Zastaprazan Compared With Esomeprazole in Erosive Esophagitis
4个月前
已完结
Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)
4个月前
已完结
皖公网安备34019202002308
